Tempest Therapeutics Inc (TPST)

Jun 14, 2025

Millennium Management LLC Acquires Shares of 189,506 Tempest Therapeutics, Inc. (NASDAQ:TPST) - Defense World

Jun 14, 2025

Jun 12, 2025

Tempest Therapeutics Secures $4.1M in Direct Offering - TipRanks

Jun 12, 2025

Jun 12, 2025

SEC Form 424B5 filed by Tempest Therapeutics Inc. - Quantisnow

Jun 12, 2025

Jun 12, 2025

Form 424B5 Tempest Therapeutics, - StreetInsider

Jun 12, 2025

Jun 11, 2025

Tempest Therapeutics Announces $4.6 Mln Registered Direct Offering With Institutional Investor - Nasdaq

Jun 11, 2025

Jun 11, 2025

Tempest Therapeutics (TPST) Announces New Stock Purchase Agreeme - GuruFocus

Jun 11, 2025

Jun 11, 2025

Tempest Therapeutics ends ATM prospectus with Jefferies By Investing.com - Investing.com Canada

Jun 11, 2025

Jun 11, 2025

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock - The Manila Times

Jun 11, 2025

Jun 11, 2025

Tempest Therapeutics, Inc. Announces $4.6 Million Registered Direct Offering of Common Stock - Nasdaq

Jun 11, 2025

Jun 11, 2025

Tempest Therapeutics announces $4.6 million registered direct offering - Investing.com

Jun 11, 2025

Jun 11, 2025

Tempest Therapeutics ends ATM prospectus with Jefferies - Investing.com

Jun 11, 2025

Jun 11, 2025

Tempest Therapeutics Terminates ATM Prospectus Supplement Dated February 6, 2025SEC Filing - MarketScreener

Jun 11, 2025

Jun 09, 2025

Why Circle Internet Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Benzinga

Jun 09, 2025

Jun 09, 2025

Pre-market Movers: KLTO, TPST, PYPD, MOVE... - RTTNews

Jun 09, 2025

Jun 06, 2025

Tempest Therapeutics Shifts Executives to Consulting Roles - TipRanks

Jun 06, 2025

Jun 05, 2025

Tempest Therapeutics stock rises on EMA Orphan Drug Designation By Investing.com - Investing.com South Africa

Jun 05, 2025

Jun 05, 2025

Tempest Therapeutics stock rises on EMA Orphan Drug Designation - Investing.com

Jun 05, 2025

Jun 05, 2025

Tempest Therapeutics Says Amezalpat Gets EMA Orphan Drug Designation in Liver Cancer - marketscreener.com

Jun 05, 2025

Jun 05, 2025

Tempest Therapeutics: European Medicines Agency Grants Orphan Drug Designation To Amezalpat - Nasdaq

Jun 05, 2025

Jun 05, 2025

TPST Receives EMA Orphan Drug Designation for Liver Cancer Treatment | TPST Stock News - GuruFocus

Jun 05, 2025

Jun 05, 2025

Tempest Receives Orphan Drug Designation from the European - GlobeNewswire

Jun 05, 2025

May 23, 2025

Tempest Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 23, 2025

May 19, 2025

HC Wainwright Issues Optimistic Estimate for TPST Earnings - Defense World

May 19, 2025

May 16, 2025

Tempest Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 16, 2025

May 16, 2025

Layoff Tracker: Allogene Cuts 28% of Staff to Extend Runway, Focus on Clinical Programs - BioSpace

May 16, 2025

May 14, 2025

TPST Highlights Promising Data for Cancer Therapy | TPST Stock N - GuruFocus

May 14, 2025

May 14, 2025

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times

May 14, 2025

May 13, 2025

Tempest Therapeutics Q1 Operating Income USD -10.936 Million - marketscreener.com

May 13, 2025

May 13, 2025

Tempest Therapeutics Reports Positive Amezalpat Data and FDA Designations for Cancer Treatment Programs - Nasdaq

May 13, 2025

May 13, 2025

FDA Grants Multiple Key Designations to Tempest Cancer Drugs as New AACR Data Shows Promise - Stock Titan

May 13, 2025

May 11, 2025

Millendo Therapeutics, Inc. Announces Board Changes - marketscreener.com

May 11, 2025

May 08, 2025

Cash-strapped Bay Area biotech company lays off all but 5 employees - MSN

May 08, 2025

May 05, 2025

Tempest Therapeutics Inc expected to post a loss of $3.29 a shareEarnings Preview - TradingView

May 05, 2025

May 04, 2025

Geode Capital Management LLC Has $296,000 Stake in Tempest Therapeutics, Inc. (NASDAQ:TPST) - Defense World

May 04, 2025

May 03, 2025

TPSTTempest Therapeutics Inc Latest Stock News & Market Updates - Stock Titan

May 03, 2025

Apr 30, 2025

XTX Topco Ltd Has $134,000 Position in Tempest Therapeutics, Inc. (NASDAQ:TPST) - Defense World

Apr 30, 2025

Apr 29, 2025

Tempest Therapeutics regains Nasdaq compliance By Investing.com - Investing.com Canada

Apr 29, 2025

Apr 28, 2025

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting - The Manila Times

Apr 28, 2025

Apr 28, 2025

Tempest Therapeutics Presents Promising Amezalpat Data at 2025 AACR Annual Meeting, Supporting Novel Cancer Treatment Mechanism - Nasdaq

Apr 28, 2025

Apr 28, 2025

Tempest Presents New Amezalpat MOA Data Reinforcing Its - GlobeNewswire

Apr 28, 2025

Apr 28, 2025

Breakthrough: New Cancer Drug Amezalpat Demonstrates Dual Anti-Cancer Mechanism in Multiple Tumors - Stock Titan

Apr 28, 2025

Apr 28, 2025

Tempest Therapeutics regains Nasdaq compliance - Investing.com

Apr 28, 2025

Apr 27, 2025

Market Recap Check: Tempest Therapeutics Inc (TPST)’s Negative Finish at 0.61, Up/Down -14.53 - DWinneX

Apr 27, 2025

Apr 24, 2025

Struggling Bay Area biotech company, once worth $1B, lays off all but 5 workers - SFGATE

Apr 24, 2025

Apr 22, 2025

Tempest Therapeutics - The Pharma Letter

Apr 22, 2025

Apr 21, 2025

Tempest Therapeutics stock rises on FDA Orphan Drug Designation By Investing.com - Investing.com Nigeria

Apr 21, 2025

Apr 21, 2025

Tempest Therapeutics stock rises on FDA Orphan Drug Designation - Investing.com Australia

Apr 21, 2025

Apr 21, 2025

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP - The Manila Times

Apr 21, 2025